Evidence map›Paper›PMID 39072173›Full record

ReviewWorld journal of gastrointestinal oncology2024

Role of molecular biology in the management of pancreatic cancer.

Alice Boileve, Cristina Smolenschi, Aurélien Lambert, Valérie Boige, Anthony Tarabay, Marine Valery, Alina Fuerea, Thomas Pudlarz, Thierry Conroy, Antoine Hollebecque and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastrointestinal oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alice BoileveDepartment of Medical, Gustave Roussy, Villejuif 94800, France. alice.boileve@gustaveroussy.fr.
Cristina SmolenschiDepartment of Medical, Gustave Roussy, Villejuif 94800, France.
Aurélien LambertDepartment of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy 54519, France.
Valérie BoigeDepartment of Medical, Gustave Roussy, Villejuif 94800, France.
Anthony TarabayDepartment of Medical, Gustave Roussy, Villejuif 94800, France.
Marine ValeryDepartment of Medical, Gustave Roussy, Villejuif 94800, France.
Alina FuereaDepartment of Medical, Gustave Roussy, Villejuif 94800, France.
Thomas PudlarzDepartment of Medical, Gustave Roussy, Villejuif 94800, France.
Thierry ConroyDepartment of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy 54519, France.
Antoine HollebecqueDepartment of Medical, Gustave Roussy, Villejuif 94800, France.
Michel DucreuxDepartment of Medical, Gustave Roussy, Villejuif 94800, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) presents significant challenges in patient management due to a dismal prognosis, increasing incidence, and limited treatment options. In this regard, precision medicine, which personalizes treatments based on tumour molecular characteristics, has gained great interest. However, its widespread implementation is not fully endorsed in current recommendations. This review explores key molecular alterations in PDAC, while emphasizing differences between

Indexed as

KRASLiquid biopsyMolecular profilePancreatic cancerPrecision medicineTargeted therapies

Identifiers

PMID39072173
PMCPMC11271790

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.